ESC 365 - What value do SGLT2 inhibitors offer to patients hospitalised for heart failure?

Open Access

What value do SGLT2 inhibitors offer to patients hospitalised for heart failure?

Session: Practical guidance to implement heart failure treatment with SGLT2 inhibitors in the hospital setting

Topic: Treatment

Speaker: Professor J. Teerlink (San Francisco, US)

Sponsored by Boehringer Ingelheim and Eli Lilly and Company

Event: ESC Congress 2023

Congress Presentation

About the speaker

Professor John R Teerlink

San Francisco Veterans Affairs Medical Centre, San Francisco (United States of America)

35 presentations

0 follower

4 more presentations in this session

Welcome and introduction

Speaker: Professor I. Pina (Philadelphia, US)

2023 heart failure guideline recommendations: where do we stand?

Speaker: Doctor A. Bayes Genis (Badalona, ES)

Starting SGLT2 inhibitors in practice: considerations for implementation in the hospital setting

Speaker: Doctor M. Kosiborod (Kansas City, US)

Audience questions and close

Access the full session

Practical guidance to implement heart failure treatment with SGLT2 inhibitors in the hospital setting

Speakers: Professor J. Teerlink, Professor I. Pina, Doctor A. Bayes Genis, Doctor M. Kosiborod

About the event

ESC Congress 2023

25 August - 28 August 2023

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources